Phosphodiesterase-4 in Atopic dermatitis, systematic review

Introduction: Atopic Dermatitis (AD) is a chronically relapsing, non-contagious, pruritic skin disorder that causes dry and flaky skin with thickening. Phosphodiesterase-4 is one of the main targets for treatment of AD. Objective: To represent a solid comprehensive overview about Phosphodiesterase-4 levels in Atopic dermatitis. Source: Web of Science database core collection, and Scopus database. Methodology: Systematic review papers with or without a meta-analysis on the Phosphodiesterase-4 levels in Atopic dermatitis have been included. The estimated plausible hazard of unfairness was performed by recording, reportage and methodological quality of the selected systematic reviews. Design: A systematic review Data sources: An electronic search of Scopus, and the Web of Science was completed up to June 2021. The data included basic characteristics, and related complications were examined and recorded. Review methods: Eligibility and methodological quality of the studies were assessed by the authors independently. Results: 64 review articles were recorded for both Phosphodiesterase-4 and Atopic dermatitis simultaneously in Scopus database while 66 review articles were recorded in web of science in June 2021. Conclusion: The relation between Phosphodiesterase-4 and atopic dermatitis was confirmed whereas, Phosphodiesterase 4 (PDE4) regulates cyclic adenosine monophosphate in cells and has been shown to be involved in the pathophysiology of AD, making it an attractive therapeutic target.